Also known as: OliX Pharmaceuticals
Olix Pharmaceuticals is a clinical-stage biotechnology company developing RNA interference therapeutics and platform technologies for multiple diseases.
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
